Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

First line drug treatment of this indication - in combination with obinutuzumab

The condition must be untreated with drug treatment at the time of the first dose of this drug; or

Patient must have developed an intolerance of a severity necessitating permanent treatment withdrawal following use of another drug PBS indicated as first-line drug treatment of CLL/SLL; AND

The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition; AND

The treatment must be initiated as a monotherapy for 1 Cycle with treatment in combination with obinutuzumab from Cycle 2 to 7 (refer to Product Information for timing of obinutuzumab and acalabrutinib doses) after which treatment must be monotherapy; AND

The treatment must not be in combination with venetoclax; AND

Patient must be undergoing initial treatment with this drug - this is the first prescription for this drug; or

Patient must be undergoing continuing treatment with this drug - the condition has not progressed whilst the patient has actively been on this drug; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.